Urs Beat Hagemann

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Omeros Corporation, Cancer Research Technology Limited, Affitech Research as. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Urs Beat Hagemann. Retrieved from https://idiyas.com/inventor/urs-beat-hagemann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 19(Granted Patents)

Company Filing History:

Cancer Research Technology Limited

Years Active: 2014-2023

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11613589 - Compositions for inhibiting MASP-2 dependent complement activation (2023-03-28),

2. 10683367 - Compositions for inhibiting MASP-2 dependent complement activation (2020-06-16),

3. 10266599 - Antibodies which bind to the human CC chemokine receptor 4 and uses thereof (2019-04-23),

4. 10047165 - Compositions for inhibiting MASP-2 dependent complement activation (2018-08-14),

5. 9475885 - Compositions for inhibiting MASP-2 dependent complement activation (2016-10-25),

6. 9458238 - Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof (2016-10-04),

7. 9011860 - Compositions for inhibiting MASP-2 dependent complement activation (2015-04-21),

8. 8969253 - Method for screening phage display libraries against each other (2015-03-03),

9. 8895007 - Antibodies which bind to the human CC chemokine receptor 4 and uses thereof (2014-11-25),

Title: Urs Beat Hagemann: Innovator in Complement Activation Inhibition

Introduction

Urs Beat Hagemann is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of biotechnology, particularly in the area of complement activation inhibition. With a total of nine patents to his name, Hagemann's work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Hagemann's latest patents focus on compositions for inhibiting MASP-2 dependent complement activation. The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation. This innovative approach aims to provide new avenues for treatment in conditions where complement activation plays a detrimental role.

Career Highlights

Throughout his career, Hagemann has worked with prominent organizations, including Omeros Corporation and Cancer Research Technology Limited. His experience in these companies has allowed him to develop and refine his inventions, contributing to advancements in medical science.

Collaborations

Hagemann has collaborated with notable professionals in his field, including Herald Reiersen and Thomas Dudler. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Urs Beat Hagemann is a distinguished inventor whose work in complement activation inhibition holds promise for future therapeutic developments. His contributions to biotechnology and collaboration with industry professionals underscore the importance of innovation in addressing complex medical challenges.

Profile summary based on public USPTO records.